Cartesian Therapeutics Chair Carrie Cox resigns; CEO Carsten Brunn named Chairman, bylaw amended

Cartesian Therapeutics, Inc.

Carrie Cox resigned from the Board and as Chair on Oct. 29, 2025, to focus on other commitments; not related to any disagreement.
Carsten Brunn, Ph.D., CEO and Board member, appointed Chairman of the Board effective immediately.
Patrick Zenner named Lead Independent Director; Kemal Malik appointed Chairman of the Compensation Committee.
Board approved amended and restated Bylaws to incorporate references to Lead Independent Director.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Cartesian Therapeutics, Inc.: Board approved amendment and restatement of bylaws to include references to the position of Lead Independent Director (effective 2025-10-29).

Change: bylaw amendment
Effective: 2025-10-29

Exact text from the filing

On October 29, 2025, the Board approved an amendment and restatement of the Company’s Amended and Restated Bylaws, which became effective the same day. The Amended and Restated Bylaws now include appropriate references to the position of Lead Independent Director of the Board.

View on SEC.gov

89 governance changes filed in the last 30 days. Browse all governance changes →

Cartesian Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-25-039793

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.